In Oct 2013, the FDA permitted labeling changes for ezogabine, together with a boxed warning, emphasizing elevated risks for likely permanent adverse results, including retinal abnormalities, eyesight loss, and pores and skin discoloration. The company proposed that the usage of ezogabine be limited to individuals who've experienced an inadequate r… Read More